Diagnostic technology – Mostobd http://mostobd.com/ Wed, 10 Nov 2021 00:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://mostobd.com/wp-content/uploads/2021/11/favicon-1-120x120.png Diagnostic technology – Mostobd http://mostobd.com/ 32 32 Philips to acquire Cardiologs, developer of AI-based cardiac diagnostic technology https://mostobd.com/philips-to-acquire-cardiologs-developer-of-ai-based-cardiac-diagnostic-technology/ https://mostobd.com/philips-to-acquire-cardiologs-developer-of-ai-based-cardiac-diagnostic-technology/#respond Mon, 08 Nov 2021 18:23:39 +0000 https://mostobd.com/philips-to-acquire-cardiologs-developer-of-ai-based-cardiac-diagnostic-technology/ [Image from Philips/Cardiologs] Royal Philips (NYSE: PHG) announced today that it has signed an agreement to acquire Cardiologs and its artificial intelligence (AI) -based technology. Amsterdam-based Philips said in a press release that France-based Cardiologs and its artificial intelligence and cloud technology will further strengthen its cardiac monitoring and diagnostic offerings with innovative software, analysis […]]]>
[Image from Philips/Cardiologs]

Royal Philips (NYSE: PHG) announced today that it has signed an agreement to acquire Cardiologs and its artificial intelligence (AI) -based technology.

Amsterdam-based Philips said in a press release that France-based Cardiologs and its artificial intelligence and cloud technology will further strengthen its cardiac monitoring and diagnostic offerings with innovative software, analysis services and electrocardiogram (ECG) report.

Financial terms of the transaction were not disclosed. The companies expect the transaction to close in the coming months, subject to customary closing conditions.

Cardiologs’ offerings include a vendor-independent cardiac disorder screener and ECG analysis applications based on machine learning algorithms. The company designed its technology to speed diagnostic reporting, reduce reporting errors, and streamline clinician workflow and patient care. Its technology holds CE mark and FDA clearance for the detection of cardiac arrhythmias.

“Offering superb clinical insights, along with automated clinical reports, Cardiologs medical grade AI technology and data scientists will be an important addition to our growing portfolio of cardiac solutions for hospitals and outpatient facilities,” Philips Chief Business Leader for Connected Care Roy Jakobs noted in the output.

“Philips’ global footprint can accelerate the availability of Cardiologs technology to patients around the world and achieve the quadruple goal of a better patient care experience, better health outcomes, a better patient experience. personnel and a lower cost of care. “

Cardiologs, founded in 2014, currently has around 70 employees, mostly software engineers and data scientists, who will join Philips and expand its AI-driven innovation activities with its R&D lab in Paris.


Source link

]]>
https://mostobd.com/philips-to-acquire-cardiologs-developer-of-ai-based-cardiac-diagnostic-technology/feed/ 0
Scientists create rapid diagnostic technology to detect SARS-CoV-2 https://mostobd.com/scientists-create-rapid-diagnostic-technology-to-detect-sars-cov-2/ https://mostobd.com/scientists-create-rapid-diagnostic-technology-to-detect-sars-cov-2/#respond Sat, 06 Nov 2021 18:43:00 +0000 https://mostobd.com/scientists-create-rapid-diagnostic-technology-to-detect-sars-cov-2/ Combining experts in molecular genetics, chemistry and the health sciences, researchers at the University of California at San Diego have created rapid diagnostic technology that detects SARS-CoV-2, the coronavirus that causes COVID-19. The new SENSR (sensitive enzymatic nucleic acid sequence reporter), described in an article published in the journal ACS sensors, is based on CRISPR […]]]>

Combining experts in molecular genetics, chemistry and the health sciences, researchers at the University of California at San Diego have created rapid diagnostic technology that detects SARS-CoV-2, the coronavirus that causes COVID-19.

The new SENSR (sensitive enzymatic nucleic acid sequence reporter), described in an article published in the journal ACS sensors, is based on CRISPR gene editing technology which enables rapid detection of pathogens by identifying genetic sequences in their DNA or RNA.

Currently, many human pathogens are detected using a method known as real-time polymerase chain reaction. Although very precise and sensitive, these diagnoses are time consuming and require specialized laboratory equipment, which limits their use to healthcare and specialized establishments. SENSR is designed to simplify the process of detecting SARS-CoV-2 for possible adaptation for home use.

While the Cas9 enzyme has been widely used in CRISPR genetic engineering research, scientists have recently used other enzymes such as Cas12a and Cas13a for the development of very accurate CRISPR-based diagnostics. Developed in the same vein, SENSR is the first diagnosis of SARS-CoV-2 to exploit the enzyme Cas13d (in particular a ribonuclease effector called “CasRx”).

The researchers believe that in order to maximize the capabilities of CRISPR and extend the genetic diagnostics pipeline, all Cas enzymes that can complement or complement existing systems should be explored.

CRISPR has dramatically improved our capabilities to quickly identify infected people and offer point-of-care testing in low-resource environments, which was not possible before. SENSR further opens the toolbox for CRISPR diagnostic systems and will help detect emerging pathogens before they become pandemics. “

Omar Akbari, lead author of the study, professor of biological sciences, UC San Diego

In developing SENSR, Akbari’s Molecular Genetics Laboratory worked in collaboration with the laboratory of Professor Elizabeth Komives of the Department of Chemistry and Biochemistry (Division of Physical Sciences) to purify SENSR proteins and the laboratory of Rob Knight of the Department of pediatrics (School of Medicine and Microbiome Innovation Center) to test SARS-CoV-2 samples.

SENSR is one of the latest developments in UC San Diego’s innovative approach to tackling the COVID-19 pandemic. The university’s scientifically recognized return to learning strategy for campus safety includes Knight’s groundbreaking wastewater screening program which has resulted in the early detection of 85% of COVID-19 cases on campus. With nearly 10,000 students on campus in the current academic year, the Return to Learn program strategy, which includes high vaccination rates, has led to a COVID-19 case rate of less than 1% , becoming a model for other academic institutions.

The first tests of the development of SENSR demonstrated the detection of SARS-CoV-2 in less than an hour. The researchers note in the article that further development is needed, but the technology has the potential to become “powerful molecular diagnostics with many applications.”

Ultimately, Akbari envisions SENSR becoming important in places such as airports so that passengers can quickly determine if they are carriers of a virus.

“We must continue to innovate in the field of detection and protection to offer more tools. Thus, in the event of a new pandemic, we will have scalable diagnostic systems at the point of care for rapid distribution”, Akbari said.

The article published in ACS sensors brought together a mix of UC San Diego graduate students, postdoctoral fellows, project scientists, and faculty members. They include: Daniel Brogan, Duverney Chaverra-Rodriguez, Calvin Lin, Andrea Smidler, Ting Yang, Lenissa Alcantara, Junru Liu, Robyn Raban, Pedro Belda-Ferre, Rob Knight, Elizabeth Komives and Omar Akbari. Igor Antoshechkin of CalTech is also a co-author.

Research funding was provided by: UC San Diego seed funds for emerging research related to COVID-19; a Directors New Innovator Award from the National Institutes of Health / National Institute of Allergy and Infectious Diseases (NIH / NIAID) (DP2 AI152071-01 and R21 (1R21AI149161); a grant from the DARPA Safe Genes Program (HR0011-17- 2-0047); a Director’s Pioneer Award from the National Center for Complementary and Integrative Health (DP1 AT010885); the NIH Molecular Biophysics Training Fellowship (T32 GM00832); the Return to Learn program from UC San Diego via the laboratory EXCITE (EXpedited COVID-19 Identification Environment); and Molecular Biophysics Training Grant, NIH Grant (T32 GM00832).

Source:

Journal reference:

Brogan, DJ, et al. (2021) Development of a rapid and sensitive diagnostic test based on CasRx for SARS-CoV-2. ACS sensors. doi.org/10.1021/acssensors.1c01088.


Source link

]]>
https://mostobd.com/scientists-create-rapid-diagnostic-technology-to-detect-sars-cov-2/feed/ 0
Former General Surgeon Joins Local Diagnostic Technology Company as Advisor | Business Observer https://mostobd.com/former-general-surgeon-joins-local-diagnostic-technology-company-as-advisor-business-observer/ https://mostobd.com/former-general-surgeon-joins-local-diagnostic-technology-company-as-advisor-business-observer/#respond Tue, 12 Oct 2021 20:28:15 +0000 https://mostobd.com/former-general-surgeon-joins-local-diagnostic-technology-company-as-advisor-business-observer/ SARASOTA – After serving as the 20th Surgeon General of the United States, Dr. Jerome Adams joins Lumos Diagnostic as a Strategic Healthcare Advisor. Lumos, a rapid point-of-service (POC) diagnostic technology company founded in Lakewood Ranch, also appointed Adams to the company’s medical advisory board, according to a statement. As a strategic healthcare advisor, Adams […]]]>

SARASOTA – After serving as the 20th Surgeon General of the United States, Dr. Jerome Adams joins Lumos Diagnostic as a Strategic Healthcare Advisor.

Lumos, a rapid point-of-service (POC) diagnostic technology company founded in Lakewood Ranch, also appointed Adams to the company’s medical advisory board, according to a statement. As a strategic healthcare advisor, Adams will provide advice on the effective deployment of POC diagnostic technologies, with the first task being the launch of FebriDx, a new finger blood test that can differentiate whether a person has a bacterial infection or viral.

“The pressing health challenges of the past 18 months have highlighted the importance of diagnostic testing as one of the key tools in addressing both the current pandemic and the looming pandemic of antimicrobial resistance,” Adams said in the press release. “We need to anticipate these problems with a truly accessible outpatient solution. “

“Lumos found a match in our passion for public health in Dr. Adams,” added Dr. Rob Sambursky, president and CEO of Lumos, in the release. “Together, we intend to have a significant impact on millions of patients each year by improving global access to innovative and cost-effective rapid diagnostic test solutions. “

While Adams was a general surgeon between 2017 and 2021, he served on the front lines of the US response to COVID-19. He has also worked to combat the opioid epidemic, increasing rates of chronic disease, the impacts of increasing suicide rates, promoting maternal health and helping businesses promote community health and equitable access to health care resources, the release said, He is currently an assistant professor of clinical anesthesia at Indiana University and practices as a staff anesthesiologist at Eskenazi Health.

Lumos Diagnostics, a Carlsbad, California-based company merged with Lakewood Ranch-based RPS Diagnostics in 2019. Following the merger, the company received a $ 15 million investment from Planet Innovation, a company Australian health technology innovation and commercialization. Lumos is a subsidiary of Planet Innovation. The investment was made to support the international business expansion of the FebriDX test.


Source link

]]>
https://mostobd.com/former-general-surgeon-joins-local-diagnostic-technology-company-as-advisor-business-observer/feed/ 0
Seegene marks new milestone in popularization of molecular diagnostic technology https://mostobd.com/seegene-marks-new-milestone-in-popularization-of-molecular-diagnostic-technology/ https://mostobd.com/seegene-marks-new-milestone-in-popularization-of-molecular-diagnostic-technology/#respond Thu, 23 Sep 2021 07:00:00 +0000 https://mostobd.com/seegene-marks-new-milestone-in-popularization-of-molecular-diagnostic-technology/ Seegene Inc., South Korea’s largest point-of-service diagnostic kit manufacturer, will mark another milestone in popularizing molecular diagnostic technology with an advanced polymerase chain reaction (PCR) machine in time. real to detect various viruses, including Covid variants in the clinical ward, helping authorities respond more quickly to the spread of the virus. The new test called […]]]>

Seegene Inc., South Korea’s largest point-of-service diagnostic kit manufacturer, will mark another milestone in popularizing molecular diagnostic technology with an advanced polymerase chain reaction (PCR) machine in time. real to detect various viruses, including Covid variants in the clinical ward, helping authorities respond more quickly to the spread of the virus.

The new test called AIOS will be presented for the first time at the opening of the American Association for Clinical Chemistry (AACC) to be held in Atlanta from September 26 to 30, according to sources close to the company on Thursday.

The AACC houses the latest technology and information on various diagnostic equipment, reagents, and test methods. Seegene, whose annual sales reached $ 1 billion last year, is one of the most notable companies among this year’s AACC presenters.

According to the sources, AIOS can perform the entire process of molecular diagnostics, such as nucleic acid extraction, PCR testing, and reading of results, with one system after sample collection.

Depending on the type of reagents, AIOS can detect up to 10 types of viruses including Covid-19 variants at the same time, or up to 15 types of respiratory viruses except Covid viruses. It weighs about a third less than the bulky all-in-one PCR equipment that weighs 1 to 1.5 tonnes. The new equipment comes in the form of a separate set into two compact devices to allow transport and installation in small clinics.

Sales are expected to start worldwide at the start of the new year. Seegene will mark its 20th anniversary with the launch of AIOS which will make advanced molecular diagnostics available in most small and medium-sized hospitals and neighborhood clinics which account for 39% of patient beds compared to 9% of large hospitals in Korea, according to the sources.

By Kim Si-gyun and Minu Kim

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]


Source link

]]>
https://mostobd.com/seegene-marks-new-milestone-in-popularization-of-molecular-diagnostic-technology/feed/ 0
Island grocers unite to raise money for diagnostic technology vital to BC Cancer https://mostobd.com/island-grocers-unite-to-raise-money-for-diagnostic-technology-vital-to-bc-cancer/ https://mostobd.com/island-grocers-unite-to-raise-money-for-diagnostic-technology-vital-to-bc-cancer/#respond Wed, 08 Sep 2021 07:00:00 +0000 https://mostobd.com/island-grocers-unite-to-raise-money-for-diagnostic-technology-vital-to-bc-cancer/ Image provided by the BC Cancer Foundation. Vancouver Island grocers are teaming up with the BC Cancer Foundation for an initiative that could save lives. They are looking to raise $ 500,000 to advance life-saving diagnostic technology that will change outcomes for prostate cancer patients in the community and beyond. From September 8 to November […]]]>

Vancouver Island grocers are teaming up with the BC Cancer Foundation for an initiative that could save lives.

They are looking to raise $ 500,000 to advance life-saving diagnostic technology that will change outcomes for prostate cancer patients in the community and beyond.

From September 8 to November 8, the Future Cures campaign will bring together local grocery brands from across the island.

Coalition partners include: 49th Parallel Grocer, Country Grocer, Fairway Markets, Quality Foods, Thrifty Foods, and Tru Value Foods.

Thrifty Foods will match all donations up to $ 125,000 through November 8.

This campaign will raise funds for PSMA-PET: an advanced imaging technology used to optimize and inform the treatment of patients with prostate cancer.

PSMA imaging scans help pinpoint the location of prostate cancer and reveal whether it has spread.

PSMA-PET funding will help make this breakthrough technology a future standard of care in British Columbia

While it varies from location to location, some stores accept in-person donations, some make a percentage of sales, some link donation online, some host events, and some accept donations directly at checkout.

This year, more than 6,000 people on Vancouver Island will be diagnosed with cancer. Prostate cancer is the most common prostate cancer in men.

To donate, click here.


Source link

]]>
https://mostobd.com/island-grocers-unite-to-raise-money-for-diagnostic-technology-vital-to-bc-cancer/feed/ 0
Bill Gates and George Soros support acquisition of UK diagnostic technology group Mologic https://mostobd.com/bill-gates-and-george-soros-support-acquisition-of-uk-diagnostic-technology-group-mologic/ https://mostobd.com/bill-gates-and-george-soros-support-acquisition-of-uk-diagnostic-technology-group-mologic/#respond Wed, 21 Jul 2021 07:00:00 +0000 https://mostobd.com/bill-gates-and-george-soros-support-acquisition-of-uk-diagnostic-technology-group-mologic/ The Soros Economic Development Fund (SEDF), founded by George Soros, with support from the Bill & Melinda Gates Foundation and several philanthropic investors, has announced the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable medical technology. As part of this initiative, the group financed the acquisition […]]]>

The Soros Economic Development Fund (SEDF), founded by George Soros, with support from the Bill & Melinda Gates Foundation and several philanthropic investors, has announced the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable medical technology.

As part of this initiative, the group financed the acquisition of the British company Mologic, a developer of lateral flow and rapid diagnostic technologies.

GAH members will invest at least £ 30million ($ 41million) in the deal.

WHY IS IT IMPORTANT

Mologic is developing tests that can help fight tropical diseases such as dengue fever, bilharzia and river blindness, as well as COVID-19.

SEDF’s investments in GAH and GAD are part of a portfolio of recent investments made in support of Open Society Foundations’ commitment to expanding global access to affordable public health products and technologies.

The initiative will aim to achieve this goal through decentralized research, development and manufacturing in and for the countries of the South.

The transaction will give the project the capacity to fill gaps in the provision of global diagnostics in low-income communities and regions.

“Testing, or diagnostics, is essential for daily public health needs, to enable physicians and healthcare professionals to provide patients with appropriate treatment as early as possible,” said Roxana Bonnell, public health expert at the Open Society Foundations. “As we saw during the COVID-19 pandemic, access to testing is absolutely essential to contain the spread of contagious diseases, an issue that ultimately affects us all.”

THE BROADER CONTEXT

Recently, Indian healthcare solutions provider HealWell24, together with actress and philanthropist Gul Panag, launched their latest web platform which provides a space for connection between doctors and patients.

ON THE RECORD

Sean Hinton, CEO of SEDF, said: “The COVID-19 pandemic has painfully demonstrated the fundamental inequalities in global public health, and in particular the critical importance of access in low- and middle-income countries to low and high prices. Quality diagnostic tools that save lives. In this unique transaction, philanthropic funds and investors work together with a knowledgeable and visionary management team in a truly innovative way to address at least part of this failure by allowing a leading commercial enterprise to focus all of its resources on solving one of the world’s most pressing public health problems.

Mark Davis, CEO of Mologic, said: “Mologic’s transition to a social enterprise is a deliberate, logical and natural step for a company focused on delivering affordable diagnostics and biotechnology to places that have been underserved by the world. relentless pursuit of profitability. With the support of our shareholders, donors and partners, we have come a long way; we believe we have the right people and skills for the challenges and opportunities ahead. And we hope this unique transaction will be an example for others to follow.


Source link

]]>
https://mostobd.com/bill-gates-and-george-soros-support-acquisition-of-uk-diagnostic-technology-group-mologic/feed/ 0
Diagnostic technology is great … until it isn’t https://mostobd.com/diagnostic-technology-is-great-until-it-isnt/ https://mostobd.com/diagnostic-technology-is-great-until-it-isnt/#respond Tue, 20 Jul 2021 07:00:00 +0000 https://mostobd.com/diagnostic-technology-is-great-until-it-isnt/ “Your efforts under bridges were undoubtedly exhausting.” –Caledon Hockley, Titanic, 1997 I once heard of a patient who developed red, edematous patches on the skin of her face that looked a lot like the lesion in her face. this photo. It was first treated as shingles and got worse. It was eventually biopsied and called […]]]>

“Your efforts under bridges were undoubtedly exhausting.”

–Caledon Hockley, Titanic, 1997

I once heard of a patient who developed red, edematous patches on the skin of her face that looked a lot like the lesion in her face. this photo. It was first treated as shingles and got worse. It was eventually biopsied and called cutaneous lymphoid hyperplasia. A number of different treatments have been tried without any improvement. He was biopsied again, same result. This time, they performed molecular genetic analysis by PCR for a rearrangement of the immunoglobulin heavy chain gene. The result, which took more than a month to return: polyclonal cutaneous lymphoid hyperplasia. Eventually, when nothing else worked, it was treated with radiation, responded beautifully like lymphomas do, and never came back.

Previously, his doctors would have looked at the clinical presentation, seen the infiltration of B cells on the pathology, called it cutaneous lymphoma, and treated accordingly, skipping almost 2 years of other management which resulted in no improvement. from this the patient’s condition.

I don’t know what I’m trying to say about this except that sometimes our new fancy tools fail us. Testing with immunohistochemistry and genetic analysis can be incredibly powerful tools in the fight against cancer. They can also lead to weeks of procrastination as the patient’s face falls. They undoubtedly avoid many situations where the patient would get the wrong treatment for what they really got, but if used improperly they can also really delay the right treatment. Time is healing.

It reminds me of a funny story from my days in the Navy. Back when Admiral (then Captain) Hyman G. Rickover was able to convince Congress to put incredibly expensive nuclear reactors in Navy ships, he was faced with a difficult dilemma: Should he take Navy ship operators and try to teach them nuclear physics, or take nuclear physicists and try to make them naval officers? He chose the latter, and to maintain quality control, personally interviewed each of them before hiring him, to the tune of tens of thousands of job interviews over the next 24 years.

The decision caused another dilemma, however. Nuclear physicists tend to get deeply involved in solving the puzzles inherent in their work. Everyone was concerned that those egg heads in the “hole” (engine room) at the bottom of the ship would focus on minor details of their surroundings, such as incoming enemy missiles, in their zeal to solve a mystery of the ship. engineering or another. The result of this concern was that each Nuke had to learn to drive the ship, so that he could imagine exactly how tense the situation on the deck must be as he worked to recover the engines / electrical system / launch catapults. planes. online again. And so it was, comrades, that yours truly learned to steer a ship the size of the Empire State Building and filled to the brim with over 5,000 of his closest friends. Turns out I’m pretty good at it and stayed there for 2 years after that, in addition to my main job with reactors.

The parallel I’m trying to draw here is that I sometimes feel like catching my diagnostic friends for as long as it takes to start treatment, just to jog their memory a little as to the state of affairs in the- above decks. But then the cooler, more rational part of my brain takes over. I would prefer that they do their job without such distractions. They really are a great team and they work very hard.

Please join the discussion below, but if you need to communicate with me offline, you can reach me at OncBlogMedscape@gmail.com.

Follow Medscape on Facebook, Twitter, Instagram, and Youtube

About Dr Kate Hitchcock

Kate Hitchcock, MD, PhD, is a retired radiation oncologist, biomedical engineer, and aircraft carrier pilot who grew up as a Wyoming cowgirl. When she’s not in the hospital, you can find her with Carolyn, Mary, Tyler, Nick, Marlee and Colby the barking dog, enjoying the natural splendor of the great state of Florida. She thinks you should visit someday and try to solve the riddle of why the natives so carefully directed all tourists to the House of the Mouse. Join her on Twitter:
@hitchcock_kate



Source link

]]>
https://mostobd.com/diagnostic-technology-is-great-until-it-isnt/feed/ 0
Soros and Gates back buyout of UK diagnostic technology group https://mostobd.com/soros-and-gates-back-buyout-of-uk-diagnostic-technology-group/ https://mostobd.com/soros-and-gates-back-buyout-of-uk-diagnostic-technology-group/#respond Sun, 18 Jul 2021 07:00:00 +0000 https://mostobd.com/soros-and-gates-back-buyout-of-uk-diagnostic-technology-group/ Philanthropists George Soros and Bill Gates are part of a consortium that buys a UK developer of testing technology that they plan to turn into a social enterprise capable of rapidly and inexpensively diagnosing tropical diseases in low-income countries. The group, led by the Soros Economic Development Fund, will invest at least £ 30million in […]]]>

Philanthropists George Soros and Bill Gates are part of a consortium that buys a UK developer of testing technology that they plan to turn into a social enterprise capable of rapidly and inexpensively diagnosing tropical diseases in low-income countries.

The group, led by the Soros Economic Development Fund, will invest at least £ 30million in Mologic, a developer of lateral flow tests, including those used for Covid-19.

In an unusual deal, Mologic, a for-profit company based in Bedford in the south-east of England, was purchased so that it could focus on manufacturing low-cost diagnostics for tropical diseases such as dengue and river blindness.

Mologic was co-founded by Professor Paul Davis, one of the creators of the original ClearBlue pregnancy test, and his son Mark. It will be renamed “Global Access Health”.

Mark Davis, Managing Director of Mologic, said it was time for people to put Africa first, not to leave it as “Ariadne’s sons”.

“The only way to do more was to disconnect from the unbridled profits,” he said.

He said a rapid antigen test was a “fantastic piece of very simple technology, where all the intellect is hidden in plain sight”. Precision rates were improving dramatically and could eventually approach those of molecular tests, he added.

Along with SEDF, the investment arm of Soros’ Open Society Foundations, the Bill & Melinda Gates Foundation is also supporting the takeover of the British company whose current owners are Foresight Group LLP and Calculus Capital. Other philanthropists also participate.

Sean Hinton, managing director of SEDF, said the new company would try to address a “classic market failure” in which the industry had failed to make testing widely available in low-income countries. Instead, he had focused on a “high cost, high impact” physician-led model in developed economies that could not be easily replicated across the world, he added.

Describing it as a “buyout for good,” Hinton said the Mologic deal was the first time the foundation has used this model. “We took out the venture capital, removed the need for return on equity, but it will continue to operate like a business,” he said.

Mologic worked with a Senegalese research institute to test a 10-minute Covid-19 diagnostic, with the goal of ultimately doing it for $ 1. Its sister company Global Access Diagnostics, also a stake in the buyout, has received millions of pounds in funding from the UK to expand manufacturing of the Covid-19 lateral flow tests.

The company’s Covid-19 tests have received CE certification, so they can be deployed by a professional in Europe, but are not yet adopted by Public Health England or approved in the United States.

Covid-19 has shown how lateral flow diagnostics can be used far beyond pregnancy tests, inexpensively to track infectious disease.

Dan Wattendorf, director of innovative technology solutions at the Gates Foundation, said the pandemic had been a “bugle call” about the importance of access to diagnostics. He said if Mologic’s social business model is successful, its use could be explored in other areas.

“The community’s lack of access to affordable and effective diagnostics for COVID – or other high-risk diseases – results in an inability to detect the disease and allocate resources to break chains of transmission,” did he declare.


Source link

]]>
https://mostobd.com/soros-and-gates-back-buyout-of-uk-diagnostic-technology-group/feed/ 0
Know Labs receives new patent for its non-invasive diagnostic technology platform, bringing the number of issued and pending patents to nearly 60 https://mostobd.com/know-labs-receives-new-patent-for-its-non-invasive-diagnostic-technology-platform-bringing-the-number-of-issued-and-pending-patents-to-nearly-60-2/ https://mostobd.com/know-labs-receives-new-patent-for-its-non-invasive-diagnostic-technology-platform-bringing-the-number-of-issued-and-pending-patents-to-nearly-60-2/#respond Tue, 22 Jun 2021 07:00:00 +0000 https://mostobd.com/know-labs-receives-new-patent-for-its-non-invasive-diagnostic-technology-platform-bringing-the-number-of-issued-and-pending-patents-to-nearly-60-2/ SEATTLE, June 22, 2021– (COMMERCIAL THREAD) –Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that it has obtained an additional patent for its Bio-RFID ™ technology, bringing its significant portfolio of patents to 57 issued and pending patents, a important step for the company. “We are building a revolutionary […]]]>

SEATTLE, June 22, 2021– (COMMERCIAL THREAD) –Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that it has obtained an additional patent for its Bio-RFID ™ technology, bringing its significant portfolio of patents to 57 issued and pending patents, a important step for the company.

“We are building a revolutionary platform technology that will revolutionize medical diagnostics, starting with what we believe to be the world’s first non-invasive glucose monitoring device,” said Phil Bosua, CEO of Know Labs and inventor of Bio -RFID. “This patent is essential because without the ability to control the timing of frequency capture, precise non-invasive measurements using radio frequency on the human body are not possible. We have obtained 22 patents to date and 35 more are pending. Our advancements will lead to breakthroughs in diagnosis and potentially disease prevention, so we pursue and implement a disciplined intellectual property strategy to protect our innovative technology and its value. ”

US Patent No. 11,033,208 was published by the United States Patent and Trademark Office and is titled “Fixed Run Time Frequency Scans for an Analyte Sensor.” The patent relates to how the operation of Know Labs’ Bio-RFID sensor technology is controlled. The detection routines conducted by the sensor to non-invasively detect an analyte in the body are conducted substantially identically to each other, which means that the results are obtained under conditions as close to the same as possible. This allows for a more accurate comparison between the results of each detection routine, increasing the precision and accuracy of Know Labs’ Bio-RFID sensor technology to non-invasively measure and identify a variety of analytes, including the glucose.

Know Labs recently announced the positive results of an independent preclinical study validating the company’s Bio-RFID technology. This recently issued patent demonstrates the accuracy and sensitivity of the sensor, which is required to pass FDA clinical trials for the company’s non-invasive blood glucose meter.

Know Labs will continue to align its product development efforts with its intellectual property strategy. The company continues to file new patents on a regular basis and will provide further details on the scope and scope of its intellectual property portfolio as the patents are issued.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the ticker symbol “KNWN”. The Company’s technology uses spectroscopy directing electromagnetic energy through a substance or material to capture a unique molecular signature. The Company calls its technology Bio-RFID ™. Bio-RFID technology can be integrated into a variety of portable, mobile, or benchtop form factors. This patented and patent-pending technology enables efficient performance of analyzes that previously could only be performed by invasive and / or expensive and time-consuming laboratory tests. The first application of our Bio-RFID technology will be in a product marketed as a glucometer. It will provide the user with real-time information on their blood sugar. This product will require approval from the United States Food and Drug Administration prior to its market introduction.

Safe Harbor Declaration

This press release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as as modified. These statements appear in several places in this release and include all statements that are not statements of historical fact concerning the intention, belief or current expectations of Know Labs, Inc., its directors or officers in this regard. which concerns, inter alia: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) product performance. You can identify these statements using the words “may”, “will”, “could”, “should”, “should”, “plans”, “expects”, “anticipates”, “continue”, “Estimate,” “plan”, “intention”, “probable”, “forecast”, “probable”, “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the control of Know Labs, Inc., and actual results may differ materially from those projected in the forecast forward-looking statements due to various factors. These risks and uncertainties also include additional risk factors as discussed in documents filed by the Company with the United States Securities and Exchange Commission, including its annual report on Form 10-K for the year ended 30 September 2020, Forms 10-Q and 8 -K, and in other documents that we make from time to time with the Securities and Exchange Commission. These documents are available in the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of their publication. The Company assumes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210622005332/en/

Contacts

Contact from Know Labs, Inc .:
Jordyn (Theisen) Hujar
jordyn@knowlabs.co
Phone. (206) 629-6414


Source link

]]>
https://mostobd.com/know-labs-receives-new-patent-for-its-non-invasive-diagnostic-technology-platform-bringing-the-number-of-issued-and-pending-patents-to-nearly-60-2/feed/ 0
SoutheastHEALTH Introduces Rapid Diagnostic Technology to Treat Blood Infections https://mostobd.com/southeasthealth-introduces-rapid-diagnostic-technology-to-treat-blood-infections/ https://mostobd.com/southeasthealth-introduces-rapid-diagnostic-technology-to-treat-blood-infections/#respond Tue, 01 Jun 2021 07:00:00 +0000 https://mostobd.com/southeasthealth-introduces-rapid-diagnostic-technology-to-treat-blood-infections/ CAP GIRARDEAU, Missouri (KFVS) – SoutheastHEALTH has implemented cutting-edge rapid diagnostic technology to help clinicians treat serious blood infections. The new technology will help deliver antibiotic therapies faster to patients. Lauren Thomas, executive director of laboratory services at SoutheastHEALTH, said it’s crucial to get patients the best therapy quickly. “Our new system, Accelerate Pheno, is […]]]>

CAP GIRARDEAU, Missouri (KFVS) – SoutheastHEALTH has implemented cutting-edge rapid diagnostic technology to help clinicians treat serious blood infections.

The new technology will help deliver antibiotic therapies faster to patients.

Lauren Thomas, executive director of laboratory services at SoutheastHEALTH, said it’s crucial to get patients the best therapy quickly.

“Our new system, Accelerate Pheno, is designed to help clinicians achieve faster diagnostic results, which improves results, reduces the use of broad-spectrum antibiotics for bloodstream infections and shortens length of stay. patients. Equally important, this technology can help reduce a patient’s risk of developing sepsis. Our microbiology lab was able to provide Antibiotic Susceptibility Test (AST) results using the Accelerate Pheno® System up to 40 hours faster than conventional methods, ”said Thomas.

The Accelerate Pheno System is manufactured by Accelerate Diagnostics, a company based in Tucson, Arizona.

The in vitro diagnostic system identifies organisms directly from positive blood cultures and performs AST to determine which drugs, at what concentrations, may be most effective.

Traditional AST can take 48 hours or more.

The Accelerate Pheno System delivers results in about seven hours.

The South East is the first hospital in the region to use this technology.

Copyright 2021 KFVS. All rights reserved.


Source link

]]>
https://mostobd.com/southeasthealth-introduces-rapid-diagnostic-technology-to-treat-blood-infections/feed/ 0